Pharmacokinetics and pharmacogenomics study with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC)
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000006634
- Lead Sponsor
- Department of Respiratory Medicine / Keio Cancer Center, School of Medicine, Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Without concent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety, Efficacy
- Secondary Outcome Measures
Name Time Method Pharmacokinetics SNP of drug metabolism related genes